P1.11.75 A Phase 2 Study of PCSK9 Inhibitor, Alirocumab, and PD1 Inhibitor, Cemiplimab, in Advanced Immunorefractory Metastatic NSCLC
Year: 2025
Type: article
Source: Journal of Thoracic Oncology
Authors: E. Oduah, N. Ready, J. Clarke, J. Rivera Concepcion, J. Crawford, L. Alder, J. Gray, T. Stinchcombe, S. Antonia
Institutions: Duke University, Duke Cancer Institute, Moffitt Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4415519335